Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy
Source abstract
Abstract
Encapsulation of cisplatin (CDDP) into nanoparticles (NPs) with high drug loading and encapsulation efficiency has been difficult due to the poor solubility of CDDP. However, this barrier has been overcome with a reverse microemulsion method appropriating CDDP's poor solubility to our advantage promoting the synthesis of a pure cisplatin nanoparticle with a high drug loading capacity (approximately 80.8 wt %). Actively targeted CDDP NPs exhibited significant accumulation in human A375M melanoma tumor cells in vivo. In addition, CDDP NPs achieved potent antitumor efficacy through the neighboring effect at a dose of 1 mg/kg when injected weekly via iv without inducing nephrotoxicity. The neighboring effect regards an observation made in vivo when the tumor cells that took up CDDP NPs released active drug following apoptosis. Via diffusion, surrounding cells that were previously unaffected showed intake of the released drug and their apoptosis soon followed. This observation was also made in vitro when A375M melanoma tumor cells incubated with CDDP NPs exhibited release of active drug and induced apoptosis on untreated neighboring cells. However, the neighboring effect was unique to rapidly proliferating tumor cells. Liver functional parameters and H&E staining of liver tissue in vivo failed to detect any difference between CDDP NP treated and control groups in terms of tissue health. By simultaneously promoting an increase in cytotoxicity and a lesser degree of side effects over free CDDP, CDDP NPs show great therapeutic potential with lower doses of drug while enhancing anticancer effectiveness.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Chemotherapy-induced organ toxicity mitigation · Drug Transport and Resistance Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
References (28)
Show source-provided references
1. Rosenber. B. · Nature · 1965 · 205 · 69810.1038/205698a0 ↗
2. Lebwohl D. · Eur. J. Cancer · 1998 · 34 · 152210.1016/S0959-8049(98)00224-X ↗
3. Drayton R. M. · Expert Rev. Anticancer Ther. · 2012 · 12 · 27110.1586/era.11.201 ↗
4. Liang X. J. · Proc. Natl. Acad. Sci. U.S.A. · 2010 · 107 · 744910.1073/pnas.0909707107 ↗
5. Go R. S. · J. Clin. Oncol. · 1999 · 17 · 40910.1200/JCO.1999.17.1.409 ↗
6. Farokhzad O. C. · Adv. Drug Delivery Rev. · 2006 · 58 · 145610.1016/j.addr.2006.09.011 ↗
7. Davis M. E. · Nat. Rev. Drug Discovery · 2008 · 7 · 77110.1038/nrd2614 ↗
8. Klibanov A. L. · FEBS Lett. · 1990 · 268 · 23510.1016/0014-5793(90)81016-H ↗
9. Farokhzad O. C. · Expert Opin. Drug Delivery · 2006 · 3 · 31110.1517/17425247.3.3.311 ↗
10. Banerjee R. · Int. J. Cancer · 2004 · 112 · 69310.1002/ijc.20452 ↗
11. Li Z. · Mol. Pharmaceutics · 2009 · 7 · 9410.1021/mp9001415 ↗
12. Zhang C. F. · Cancer Res. · 2007 · 67 · 155510.1158/0008-5472.CAN-06-1668 ↗
13. Maeda H. · J. Controlled Release · 2000 · 65 · 27110.1016/S0168-3659(99)00248-5 ↗
14. Cabral H. · Nat. Nano · 2011 · 6 · 81510.1038/nnano.2011.166 ↗
15. Chauhan V. P. · Nat. Nanotechnol. · 2012 · 7 · 38310.1038/nnano.2012.45 ↗
16. Burger K. N. · Nat. Med. · 2002 · 8 · 8110.1038/nm0102-81 ↗
17. Hamelers I. H. · J. Liposome Res. · 2007 · 17 · 18310.1080/08982100701530290 ↗
18. Khiati S. · ACS Nano · 2011 · 5 · 864910.1021/nn202291k ↗
19. Kieler-Ferguson H. M. · Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. · 2013 · 5 · 13010.1002/wnan.1209 ↗
20. Dhar S. · Proc. Natl. Acad. Sci. U.S.A. · 2008 · 105 · 1735610.1073/pnas.0809154105 ↗
21. Li X. · Int. J. Mol. Sci. · 2013 · 14 · 1122410.3390/ijms140611224 ↗
22. Basu A. · J. Nucleic Acids · 2010 · 2010
23. Kang T.-H. · Proc. Natl. Acad. Sci. U.S.A. · 2010 · 107 · 489010.1073/pnas.0915085107 ↗
24. Newman M. S. · Cancer Chemother. Pharmacol. · 1999 · 43 · 110.1007/s002800050855 ↗
25. Comenge J. · PLoS One · 2012 · 7 · e4756210.1371/journal.pone.0047562 ↗
26. Guo, S.; Miao, L.; Wang, Y.; Huang, L.Unmodified Drug Used as a Material to Construct Nanoparticles: Delivery of Cisplatin for Enhanced Anti-Cancer Therapy.J. Controlled Release 2013, submitted for publication.10.1016/j.jconrel.2013.11.019 ↗
27. Graf N. · ACS Nano · 2012 · 6 · 453010.1021/nn301148e ↗
28. Mcgahan M. C. · Spectrochim. Acta, Part B · 1987 · 42 · 66510.1016/0584-8547(87)80122-2 ↗